Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
613.00    6.00 (0.99%)
Bid:
610.00
Ask:
612.00
Spread: 2.00 (0.328%)
Market Cap: £680.28m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Statement

29 Jul 2025 07:00

RNS Number : 8564S
Barr(A.G.) PLC
29 July 2025
 

IMMEDIATE RELEASE 29 July 2025

A.G. BARR p.l.c

("A.G. BARR" or "the Company")

 

Trading Update

 

Continued revenue & profit growth; Full Year expectations unchanged

 

A.G. BARR p.l.c., the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today announces a trading update for the 26 weeks ended 26 July 2025 (H1 2025/26).

H1 2025/26 Trading

H1 2025/26 revenue is expected to be c.£228m, c.3% up on the prior year (H1 2024/25: £221.3m). Overall, the Company's trading momentum increased as H1 progressed, with several record volume weeks in Q2.

Brand revenue performance was led by Boost which delivered strong double-digit growth. IRN-BRU and Rubicon were flat in H1, with a stronger performance in Q2. FUNKIN saw continued off-trade growth partly mitigating challenges in on-trade, with the overall trend improving during H1 and positive in Q2. 

H1 adjusted operating margin is anticipated to be ahead of last year at c.15.0% (H1 2024/25: 13.0%) driven by improved manufacturing efficiencies, on-going benefits from our strategic business improvement initiatives and continued disciplined cost management.

Strategy Update

We are pleased to announce the Company has acquired a 50.1% equity stake in Innate-Essence Ltd, for an initial consideration of £15 million. Innate-Essence is the home of The Turmeric Co., a leading brand in the functional shots market, as well as a number of other speciality health drinks.

This is consistent with the Company's strategy of acquisitions and innovation in high growth, health focused, functional beverage categories. The investment has been funded from the Company's net cash position. It is not expected to have a significant impact on revenue or profit in the current financial year.

The Company has also concluded the sale of the Strathmore brand and the Forfar production site to Tŷ Nant, negatively impacting revenue in the short-term but not profit.

Full Year Outlook

Our revenue and profit growth expectations for the full year are unchanged. We are confident that H2 will see a strong rate of year-on-year revenue growth. We have made excellent progress with operating margin during H1 and expect to deliver a full year result in line with expectations after taking into account a planned higher level of marketing activity in H2.

Euan Sutherland, Chief Executive Officer, commented:

"We are pleased to report continued revenue growth and strong profit growth in the first half of the financial year. Trading improved during H1 and we enter H2 with strong momentum and continued progress on margin improvement as our strategic initiatives continue to deliver. I am also excited about our expansion into the functional beverage segment working alongside Thomas Robson-Kanu and the Innate-Essence team. Our full year guidance remains unchanged and in line with market expectations."

For more information, please contact :

A.G. BARR  MHP GROUP

0330 390 3900 07801 894 577

Euan Sutherland, Chief Executive Officer agbarr@mhpgroup.com

Stuart Lorimer, Chief Finance and Operating Officer Oliver Hughes

Ewan Dytch, Corporate Finance Director Rachel Farrington

Veronica Farah

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUWOSRVSUBUAR
Date   Source Headline
10th Feb 20253:59 pmRNSDirector/PDMR Shareholding - Replacement
10th Feb 20253:10 pmRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSTrading Update
20th Jan 202511:00 amRNSDirector Declaration
9th Jan 20254:42 pmRNSDirector/PDMR Shareholding
7th Jan 202511:44 amRNSNotice of Trading Update
17th Dec 20249:20 amRNSDirector Declaration
9th Dec 20241:50 pmRNSDirector/PDMR Shareholding
12th Nov 20241:35 pmRNSDirector/PDMR Shareholding
4th Nov 202410:54 amRNSDirector/PDMR Shareholding
9th Oct 202410:10 amRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSInterim Results
9th Sep 20241:03 pmRNSDirector/PDMR Shareholding
4th Sep 20249:08 amRNSDirector Declaration
20th Aug 20248:39 amRNSDirector/PDMR Shareholding
8th Aug 20241:10 pmRNSDirector/PDMR Shareholding
30th Jul 20247:00 amRNSTrading Statement
8th Jul 202412:03 pmRNSDirector/PDMR Shareholding
4th Jul 202410:17 amRNSNotice of Results
1st Jul 20244:50 pmRNSDirector/PDMR Shareholding
21st Jun 20243:22 pmRNSDirector/PDMR Shareholding
10th Jun 20241:51 pmRNSDirector/PDMR Shareholding
10th Jun 20241:48 pmRNSDirector/PDMR Shareholding
4th Jun 20249:36 amRNSDirector/PDMR Shareholding
31st May 20241:54 pmRNSResult of AGM
9th May 202411:28 amRNSDirector/PDMR Shareholding
7th May 20249:06 amRNSDirector/PDMR Shareholding
23rd Apr 20249:17 amRNSAnnual Financial Report
15th Apr 20242:59 pmRNSDirector/PDMR Shareholding
9th Apr 20243:46 pmRNSDirector/PDMR Shareholding - replacement
9th Apr 20243:36 pmRNSDirector/PDMR Shareholding
9th Apr 20241:05 pmRNSDirector/PDMR Shareholding - replacement
9th Apr 202412:50 pmRNSDirector/PDMR Shareholding
5th Apr 20242:26 pmRNSDirector/PDMR Shareholding
2nd Apr 202411:15 amRNSDirector/PDMR Shareholding
28th Mar 202410:10 amRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSDirectorate changes announcement
26th Mar 20247:00 amRNSFinal Results
14th Mar 20243:01 pmRNSBusiness reorganisation
11th Mar 20248:39 amRNSDirector/PDMR Shareholding
27th Feb 20241:47 pmRNSHolding(s) in Company
8th Feb 20242:03 pmRNSDirector/PDMR Shareholding - Replacement
8th Feb 20241:51 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBoard succession announcement
1st Feb 20247:00 amRNSTrading Update
16th Jan 20247:00 amRNSNotice of Trading Update
9th Jan 20241:36 pmRNSDirector/PDMR Shareholding
14th Dec 20239:22 amRNSDirector Declaration
11th Dec 20239:47 amRNSDirector/PDMR Shareholding
17th Nov 202310:13 amRNSUpdate statement on 2023 AGM Voting Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.